Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4DMedical Ltd ( (AU:4DX) ) just unveiled an announcement.
4DMedical Limited announced the expiry of its listed options, exercisable at $0.55, with the official quotation ceasing on 25 September 2025. The company has provided instructions for holders to exercise their options before the expiry date, impacting stakeholders by potentially influencing the company’s financial strategy and market positioning.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company specializing in advanced respiratory imaging and artificial intelligence. The company offers innovative solutions like the FDA-cleared XV Lung Ventilation Analysis Software and CT:VQ™ solution, which provide enhanced diagnostic capabilities for lung diseases. These solutions are delivered through a Software-as-a-Service model, integrating seamlessly into existing hospital systems to improve physician productivity and patient care. With the acquisition of Imbio in 2023, 4DMedical has further advanced its AI capabilities, continuing to redefine respiratory disease management worldwide.
Average Trading Volume: 2,037,403
Technical Sentiment Signal: Buy
Current Market Cap: A$265.4M
For detailed information about 4DX stock, go to TipRanks’ Stock Analysis page.